Polygenic Score (PGS) ID: PGS000718

Predicted Trait
Reported Trait Beta-blocker survival benefit
Mapped Trait(s) response to beta blocker (EFO_0007766)
Released in PGS Catalog: Feb. 3, 2021
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name PRPBB_44
Development Method
Name Cox proportional hazard model + LD-clumping
Parameters Model: Death~Meta-Analysis Global Group in Chronic Heart Failure score+beta blocker propensity+beta blocker exposure+SNP+SNPxbeta blocker exposure
Variants
Original Genome Build GRCh37
Number of Variants 44
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000134
Citation (link to publication) Lanfear DE et al. Circ Heart Fail (2020)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
248 individuals (100%)
PGS Evaluation
European: 100%
3 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST010923
Europe PMC: 33012170
 248 individuals European HFPGR

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM001643 PSS000852|
European Ancestry|
1,188 individuals
 PGP000134 |
Lanfear DE et al. Circ Heart Fail (2020)
 Reported Trait: Response to beta blocker (reduction in cardiovascular death) in heart failure patients — — P-value (treatment benefit in low vs. high PRP patients): 0.046 Meta-Analysis Global Group in Chronic Heart Failure Score, beta-blocker propensity score Low polygenic response predictor score < 30th percentile of derviation group
PPM001642 PSS000851|
European Ancestry|
1,188 individuals
 PGP000134 |
Lanfear DE et al. Circ Heart Fail (2020)
 Reported Trait: Response to beta blocker (reduction in all-cause mortality) in heart failure patients — — P-value (treatment benefit in low vs. high PRP patients): 0.024 Meta-Analysis Global Group in Chronic Heart Failure Score, beta-blocker propensity score Low polygenic response predictor score < 30th percentile of derviation group
PPM018550 PSS011019|
European Ancestry|
7,141 individuals
 PGP000481 |
Lanfear DE et al. Circ Genom Precis Med (2023)
|Ext.		 Reported Trait: Survival — — beta (PRPcategory*BB-exposure): 0.576 — —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS011019 — — 7,141 individuals,
66.0 % Male samples
 — European — UKB —
PSS000851 Cases = number of cardiovascular deathsHFPGR: Patients with left ventricular ejection fraction (LVEF) <50% were included. Beta-blocker (BB) exposure was calculated from pharmacy claims (ie, drug actually dispensed to patient) and was updated over time. Beta-blocker (BB) exposure was calculated from pharmacy claims (ie, drug actually dispensed to patient) and was updated over time. TIME-CHF: Patients with analysable data and a baseline LVEF <50% were included. BB exposure was calculated from the specific drug and dose at baseline, using the same dose-equivalence scheme as HFPGR but implemented without any updates over time and without information on medication dispensing (ie, assumes patients were receiving the dose prescribed). HF-ACTION: BB exposure was calculated from the specific drug and dose at baseline, using the same dose-equivalence scheme as HFPGR but implemented without any updates over time and without information on medication dispensing (ie, assumes patients were receiving the dose prescribed). —
[
  • 200 cases
  • , 988 controls
]
 — European — HF-ACTION, HFPGR, TIME-CHF —
PSS000852 Cases = number of all cause deaths. HFPGR: Patients with left ventricular ejection fraction (LVEF) <50% were included. Beta-blocker (BB) exposure was calculated from pharmacy claims (ie, drug actually dispensed to patient) and was updated over time. Beta-blocker (BB) exposure was calculated from pharmacy claims (ie, drug actually dispensed to patient) and was updated over time. TIME-CHF: Patients with analysable data and a baseline LVEF <50% were included. BB exposure was calculated from the specific drug and dose at baseline, using the same dose-equivalence scheme as HFPGR but implemented without any updates over time and without information on medication dispensing (ie, assumes patients were receiving the dose prescribed). HF-ACTION: BB exposure was calculated from the specific drug and dose at baseline, using the same dose-equivalence scheme as HFPGR but implemented without any updates over time and without information on medication dispensing (ie, assumes patients were receiving the dose prescribed). —
[
  • 279 cases
  • , 909 controls
]
 — European — HF-ACTION, HFPGR, TIME-CHF —